MSK1 activation in acute myeloid leukemia cells with FLT3 mutations

Leukemia

Volumn 24, Issue 5, 2010, Pages 1087-1090

  Odgerel, T ^a   Kikuchi, J ^a   Wada, T ^a   Shimizu, R ^a   Kano, Y ^b   Furukawa, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b TOCHIGI CANCER CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BCR ABL PROTEIN INHIBITOR; CD135 ANTIGEN; IMATINIB; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PROTEIN MSK1; SEMAXANIB; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; LETTER; LEUKEMIA CELL; LEUKEMOGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION;

EID: 77952431053     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.48     Document Type: Letter

References (8)

1. Wadleigh M, DeAngelo DJ, Griffin JD, Stone RM. After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hemato-logic malignancies. Blood 2005; 105: 22-30.
2. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105: 54-60. (Pubitemid 40053063)
3. Thomson S, Clayton AL, Hazzalin CA, Rose S, Barratt MJ, Mahadevan LC. The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J 1999; 18: 4779-4793.
4. Furukawa Y, Vu HA, Akutsu M, Odgerel T, Izumi T, Tsunoda S et al. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus negative leukemia cell lines. Leukemia 2007; 21: 1005-1014.
5. Kim H-G, Lee KW, Cho Y-Y, Kang NJ, Oh S-M, Bode AM et al. Mitogen-and stress-activated kinase 1-mediated histone H3 phosphorylation is crucial for cell transformation. Cancer Res 2008; 68: 2538-2547.
6. Srinivasa SP, Doshi PD. Extracellular signal-regulated kinase and p38 mitogen-activated protein kinase pathways cooperate in mediating cytokine-induced proliferation of a leukemic cell line. Leukemia 2002; 16: 244-253.
7. Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L et al. Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells. J Biol Chem 2004; 279: 25345-25352.
8. Dumka D, Puri P, Carayoi N, Balachandran H, Schuster K, Verma AK et al. Activation of the p38 MAP kinase pathway is essential for the antileukemic effects of dasatinib. Leuk Lymphoma 2009; 50: 2017-2029.